New Zealand markets closed

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.72-0.19 (-2.75%)
At close: 04:00PM EDT
6.72 0.00 (0.00%)
After hours: 07:10PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
20,756
20,756
31,096
45,785
33,195
Operating expenses
Research development
117,706
117,706
117,841
94,665
78,440
Selling general and administrative
42,081
42,081
42,789
33,254
15,204
Total operating expenses
159,787
159,787
160,630
127,919
93,644
Operating income or loss
-139,031
-139,031
-129,534
-82,134
-60,449
Interest expense
1,373
1,373
2,216
2,145
1,229
Total other income/expenses net
-621
-621
-
-
-5,676
Income before tax
-131,213
-131,213
-128,175
-83,892
-66,961
Income tax expense
1,280
1,280
0
0
-626
Income from continuing operations
-132,493
-132,493
-128,175
-83,892
-66,335
Net income
-132,493
-132,493
-128,175
-83,892
-66,335
Net income available to common shareholders
-132,493
-132,493
-128,175
-83,892
-66,335
Basic EPS
-2.75
-
-2.62
-1.82
-5.83
Diluted EPS
-2.75
-
-2.62
-1.82
-5.83
Basic average shares
49,069
-
48,862
46,042
11,370
Diluted average shares
49,069
-
48,862
46,042
11,370